Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Change in Accured Expenses for 10 consecutive years, with $25.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 96.91% year-over-year to $25.8 million; the trailing twelve-month figure through Jun 2026 stood at $48.7 million (up 55.76% YoY), and the FY2025 full-year result was $37.5 million, down 14.25% from the prior year.
• Change in Accured Expenses rose to $25.8 million in Q2 2026 per KNSA's latest filing, from -$5.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $25.8 million in Q2 2026 and bottomed at -$10.6 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $6.4 million across 5 years, with a median of $6.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses plunged 456.87% in 2022, then surged 345.95% in 2023.
• Over 5 years, Change in Accured Expenses stood at -$3.8 million in 2022, then soared by 239.44% to $5.3 million in 2023, then soared by 107.96% to $11.0 million in 2024, then soared by 78.54% to $19.6 million in 2025, then jumped by 31.41% to $25.8 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $25.8 million, -$5.0 million, and $19.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.